The brand name for dabigatran is Pradaxa [1].
What is Pradaxa used for?
Pradaxa is a prescription medication used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation [2]. It is also used to treat blood clots in the legs and lungs (deep vein thrombosis and pulmonary embolism) and to prevent them from returning [2].
How does dabigatran work?
Dabigatran is a direct thrombin inhibitor [3]. Thrombin is an enzyme that plays a critical role in the blood clotting process [3]. By inhibiting thrombin, dabigatran reduces the formation of blood clots [3].
When did Pradaxa's patent expire?
The patent for dabigatran etexilate, the active ingredient in Pradaxa, has faced various challenges and has had different expiry dates depending on the region and specific patent claims. Information on patent expirations for specific drugs can be tracked through resources like DrugPatentWatch.com [4].
What are the alternatives to Pradaxa?
Other medications are available for preventing stroke and treating blood clots. These include warfarin, which is an older anticoagulant, and newer direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban, and edoxaban [5]. Each of these medications has its own profile of benefits, risks, and dosing requirements.
What are the risks and side effects of Pradaxa?
The most serious risk associated with Pradaxa, like other anticoagulants, is bleeding [2]. Bleeding can occur anywhere in the body and may be serious or life-threatening [2]. Other potential side effects include indigestion, stomach pain, nausea, and an increased risk of bruising [2]. Patients should discuss their individual risk factors for bleeding with their doctor [2].
Can generic versions of Pradaxa be made?
The availability of generic versions of Pradaxa depends on patent expirations and any ongoing legal challenges to those patents [4]. Once patents expire and regulatory hurdles are cleared, generic manufacturers may produce their own versions of dabigatran [4].